FDC

The Ministry of Health and Family Welfare released the first NLEM in 1996. It contained 279 medicines. The list was subsequently revised in 2003 and had 354 medicines

Glenmark Pharmaceuticals on Thursday said it has launched a novel fixed-dose combination (FDC) drug in the country for patients with uncontrolled asthma. The Mumbai-based drug major has launched - Indacaterol + Mometasone FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily. "Respiratory is a key focus area for Glenmark, and the company leads from the front in providing access to the latest treatment options to patients. "We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma," Glenmark Pharmaceuticals Group Vice President & Head (India Formulations) Alok Malik said in a statement. The drug maker is the first company in India to market the FDC of .

The company's board will meet on February 9, 2022 to consider the proposal for buyback of equity shares of the company through tender offer route.

The momentum indicator for FDC has reversed from the overbought territory which hints of further positive momentum in the counter

The price per tablet is Rs 55 for both the variants

In the past two months, FDC has outperformed the market by surging 25 per cent, after reporting a healthy September quarter earnings (Q2FY20)

FDC rallied 11% to Rs 319, while V-Mart surged 7% to Rs 1,960 on the BSE in intra-day trade.

The stock hit a 52-week high of Rs 280, up 10%, extending its previous days 6% surge, after the board approved buyback proposal at a price of Rs 350 per equity share through tender offer.

The stock was up 7% to Rs 256 on BSE ahead of board meeting today to consider share buyback proposal and unaudited financial results for the quarter ended December 2017.

The stock was up 6% to RS 195 on the BSE.

USFDA carried out the audit in relation to cGMP norms and the ANDA filed by the company for dorzolamide ophthalmic solution from the unit

Controversy arose after Centre banned 344 fixed dose combination drugs